GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Restart Life Sciences Corp (XCNQ:HEAL) » Definitions » Current Deferred Revenue

Restart Life Sciences (XCNQ:HEAL) Current Deferred Revenue : C$0.00 Mil (As of Mar. 2025)


View and export this data going back to 2006. Start your Free Trial

What is Restart Life Sciences Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Restart Life Sciences's current deferred revenue for the quarter that ended in Mar. 2025 was C$0.00 Mil.

Restart Life Sciences Current Deferred Revenue Historical Data

The historical data trend for Restart Life Sciences's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Restart Life Sciences Current Deferred Revenue Chart

Restart Life Sciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Restart Life Sciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Restart Life Sciences Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Restart Life Sciences's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Restart Life Sciences Business Description

Traded in Other Exchanges
Address
700 - 838 West Hastings Street, Vancouver, BC, CAN, V6C 0A6
Restart Life Sciences Corp is a Canadian life sciences company dedicated to addressing today's health challenges with wellness solutions. Its focus is on creating health foods that address the needs of this community. Its flagship developments include natural remedies for individuals on the Autism Spectrum, Specialty Health Foods, Psilocybin Clinical Trial for Fragile X Syndrome, and Orphan Drug Designation (FDA and EMA). The company operates in one industry segment, being research and development of psilocybin, and in one geographic area, being Canada.
Executives
Derek Lloyd Harry Ivany 10% Security Holder, Director, Senior Officer
Steven Feldman Director
William Rascan Director, Senior Officer

Restart Life Sciences Headlines